These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 28257576)
1. Evaluation of DILI Predictive Hypotheses in Early Drug Development. Chan R; Benet LZ Chem Res Toxicol; 2017 Apr; 30(4):1017-1029. PubMed ID: 28257576 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of Chan R; Benet LZ Toxicol Res (Camb); 2018 May; 7(3):358-370. PubMed ID: 29785262 [TBL] [Abstract][Full Text] [Related]
3. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. Chan R; Benet LZ Toxicol Sci; 2018 Apr; 162(2):499-508. PubMed ID: 29272540 [TBL] [Abstract][Full Text] [Related]
4. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. Bocci G; Oprea TI; Benet LZ AAPS J; 2022 Feb; 24(2):37. PubMed ID: 35199251 [TBL] [Abstract][Full Text] [Related]
5. Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Li J; Larregieu CA; Benet LZ Chin J Nat Med; 2016 Dec; 14(12):888-897. PubMed ID: 28262115 [TBL] [Abstract][Full Text] [Related]
6. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential. Benet LZ J Pharm Sci; 2023 Sep; 112(9):2326-2331. PubMed ID: 37429358 [TBL] [Abstract][Full Text] [Related]
7. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Vuppalanchi R; Gotur R; Reddy KR; Fontana RJ; Ghabril M; Kosinski AS; Gu J; Serrano J; Chalasani N Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1550-5. PubMed ID: 24362054 [TBL] [Abstract][Full Text] [Related]
8. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. Hosey CM; Chan R; Benet LZ AAPS J; 2016 Jan; 18(1):251-60. PubMed ID: 26589308 [TBL] [Abstract][Full Text] [Related]
9. BDDCS class prediction for new molecular entities. Broccatelli F; Cruciani G; Benet LZ; Oprea TI Mol Pharm; 2012 Mar; 9(3):570-80. PubMed ID: 22224483 [TBL] [Abstract][Full Text] [Related]
10. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties. Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588 [TBL] [Abstract][Full Text] [Related]
12. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Charalabidis A; Sfouni M; Bergström C; Macheras P Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154 [TBL] [Abstract][Full Text] [Related]
13. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626 [TBL] [Abstract][Full Text] [Related]
14. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Thakkar S; Chen M; Fang H; Liu Z; Roberts R; Tong W Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):31-38. PubMed ID: 28931315 [TBL] [Abstract][Full Text] [Related]
15. Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters. Golfar Y; Shayanfar A J Pharm Pharm Sci; 2019; 22(1):247-269. PubMed ID: 31287788 [TBL] [Abstract][Full Text] [Related]
16. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Aleo MD; Luo Y; Swiss R; Bonin PD; Potter DM; Will Y Hepatology; 2014 Sep; 60(3):1015-22. PubMed ID: 24799086 [TBL] [Abstract][Full Text] [Related]
17. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. McEuen K; Borlak J; Tong W; Chen M Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208 [TBL] [Abstract][Full Text] [Related]
18. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. Liu W; Yan T; Chen K; Yang L; Benet LZ; Zhai S Pharmacotherapy; 2020 Apr; 40(4):274-290. PubMed ID: 32100890 [TBL] [Abstract][Full Text] [Related]
19. Minimizing DILI risk in drug discovery - A screening tool for drug candidates. Schadt S; Simon S; Kustermann S; Boess F; McGinnis C; Brink A; Lieven R; Fowler S; Youdim K; Ullah M; Marschmann M; Zihlmann C; Siegrist YM; Cascais AC; Di Lenarda E; Durr E; Schaub N; Ang X; Starke V; Singer T; Alvarez-Sanchez R; Roth AB; Schuler F; Funk C Toxicol In Vitro; 2015 Dec; 30(1 Pt B):429-37. PubMed ID: 26407524 [TBL] [Abstract][Full Text] [Related]
20. Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential. Aleo MD; Shah F; Allen S; Barton HA; Costales C; Lazzaro S; Leung L; Nilson A; Obach RS; Rodrigues AD; Will Y Chem Res Toxicol; 2020 Jan; 33(1):223-238. PubMed ID: 31532188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]